Clinical Trial Update: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating mineralocorticoid receptor antagonism as an add-on in atherosclerosis has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Hyperkalemia
• Type 2 Diabetes Mellitus

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Type2 Diabetes, Hyperkalemia | Phase 4 | Status: TERMINATED | Results posted: 2022-05-16